Assessing Bio-Techne (TECH) Valuation After Earnings Beat And New 3D Research Tool Launch

Simply Wall St.02-16

AdvertisementWhy Bio-Techne Is Back on Investor Radar Bio-Techne (TECH) has drawn fresh attention after quarterly results topped Wall Street expectations, supported by large pharmaceutical customers, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611754101?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-02-16 04:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611754101","market":"nz","top_or_hot":-1,"title":"Assessing Bio-Techne (TECH) Valuation After Earnings Beat And New 3D Research Tool Launch","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Bio-Techne Is Back on Investor Radar Bio-Techne (TECH) has drawn fresh attention after quarterly results topped Wall Street expectations, supported by large pharmaceutical customers, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/assessing-bio-techne-tech-valuation-after-earnings-beat-and-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Bio-Techne (TECH) Valuation After Earnings Beat And New 3D Research Tool Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Bio-Techne (TECH) Valuation After Earnings Beat And New 3D Research Tool Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-16 04:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/assessing-bio-techne-tech-valuation-after-earnings-beat-and-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Bio-Techne Is Back on Investor Radar Bio-Techne (TECH) has drawn fresh attention after quarterly results topped Wall Street expectations, supported by large pharmaceutical customers, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/assessing-bio-techne-tech-valuation-after-earnings-beat-and-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TECH","symbol_name":"Techne Corporation","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/assessing-bio-techne-tech-valuation-after-earnings-beat-and-1","article_id":"2611754101","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/assessing-bio-techne-tech-valuation-after-earnings-beat-and-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611754101","pubTimestamp":1771186666,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Bio-Techne Is Back on Investor Radar\nBio-Techne (TECH) has drawn fresh attention after quarterly results topped Wall Street expectations, supported by large pharmaceutical customers, tighter cost control and new product momentum in 3D stem cell and organoid research tools.\nSee our latest analysis for Bio-Techne.\nThose earnings and product updates have landed against a mixed share price backdrop, with a 12.73% 1 month share price decline and an 8.58% 1 year total shareholder return...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TECH":"Techne Corporation","TECH.AU":"GLOBAL X MORNINGSTAR GLOBAL"},"translate_title":"在盈利超出预期和新3D研究工具推出后评估Bio-Techne(TECH)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH.AU":1.5,"TECH":1.5},"content_text":"AdvertisementWhy Bio-Techne Is Back on Investor Radar Bio-Techne (TECH) has drawn fresh attention after quarterly results topped Wall Street expectations, supported by large pharmaceutical customers, tighter cost control and new product momentum in 3D stem cell and organoid research tools. See our latest analysis for Bio-Techne. Those earnings and product updates have landed against a mixed share price backdrop, with a 12.73% 1 month share price decline and an 8.58% 1 year total shareholder return decline, in contrast with a modestly positive 90 day share price return and a 5 year total shareholder return decline of 37.13%. This suggests that longer term sentiment has been weak even as near term interest has picked up. If Bio-Techne's focus on advanced research tools has caught your attention, it could be a good moment to broaden your watchlist with 25 healthcare AI stocks surfaced by our screener. With the share price under pressure, annual net income growth of 23.82% and a market price below some estimated values, you have to ask yourself: is Bio-Techne being overlooked, or is the market already pricing in its next chapter? Most Popular Narrative: 14.4% Undervalued With Bio-Techne last closing at $59.93 and the widely followed fair value estimate sitting at $70.00, the narrative suggests the market is not fully reflecting its long term cash flow potential, even after the recent share price weakness.  The company's shift in portfolio focus, highlighted by the divestiture of Exosome Diagnostics, allows redeployment of capital and resources toward higher margin core business segments and growth pillars, supporting both immediate operating margin improvement (expected 100 to 200 basis point expansion) and higher future earnings.  Read the complete narrative. Curious how this margin story turns into that higher fair value? The narrative leans on steady top line progress, sharper profitability, and a richer earnings multiple. Want to see how those pieces fit together and what assumptions sit behind them? Result: Fair Value of $70.00 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you still need to weigh the hit from weaker biotech and academic funding, as well as the possibility that rising competition squeezes Bio-Techne's margins over time. Find out about the key risks to this Bio-Techne narrative. Another Way To Look At The Valuation Our fair value estimate suggests Bio-Techne is undervalued by about 17.6%, yet the current P/E of 115.7x is far above the fair ratio of 25.3x, the US Life Sciences industry at 35.2x, and peer average of 27.2x. That gap points to real valuation risk if sentiment shifts, so which signal do you trust more? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:TECH P/E Ratio as at Feb 2026 Build Your Own Bio-Techne Narrative If you are not fully on board with this view, or simply want to stress test the assumptions yourself, you can build your own Bio-Techne story in just a few minutes and Do it your way. A great starting point for your Bio-Techne research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? If Bio-Techne has you thinking more critically about price and quality, now is the time to widen your search and give yourself better options.  Target strong value by scanning our list of 53 high quality undervalued stocks that pair appealing prices with robust fundamentals. Prioritise staying power by zeroing in on companies from our solid balance sheet and fundamentals stocks screener (45 results) that can better handle tough conditions. Spot potential early movers by reviewing our screener containing 23 high quality undiscovered gems before they are widely talked about.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Bio-Techne might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611754101","isCrawlerRequest":true}